CytoAgents is focused on developing CTO1681, an innovative oral therapy designed to treat Cytokine Release Syndrome (CRS), a severe immune response often triggered by treatments like CAR T-cell therapy. CTO1681 functions as a steroid-sparing immunomodulator that effectively downregulates over 25 cytokines associated with CRS, thereby mitigating the dangerous effects of a cytokine storm. The therapy is currently undergoing a Phase 1b/2a clinical trial, specifically targeting CRS in patients receiving CAR T-cell therapy, which is known to induce significant immune responses that can lead to hospitalization and intensive care.

The mechanism of action for CTO1681 involves targeting the NF-kB signaling pathway, which is crucial for the activation and regulation of inflammatory immune cells. By interrupting this pathway, CTO1681 can prevent the amplification of cytokine production while preserving the overall functionality of the immune system. This unique approach not only aims to treat CRS effectively but also holds the potential to prevent it, thereby improving patient outcomes and expanding access to vital immunotherapies in oncology.

United States

CytoAgents is developing innovative pharmaceutical products to treat life-threatening conditions, diseases, and disorders associated with Cytokine Release Syndrome (CRS). Led by CEO Teresa Whalen, CytoAgents is comprised of seasoned business leaders and medical professionals focused on developing innovative treatments. The company is a clinical-stage biotechnology company with a therapeutic focus on oncology.

CytoAgents

Company Details